BD Names Gary Sorsher Chief Quality Officer as Jeff Silvestri Prepares to Retire
The medical technology giant announces a leadership transition in its quality organization, effective September 8.
Leadership Transition in Quality Operations
Becton, Dickinson and Company (NYSE: BDX) announced Monday that Gary Sorsher will join the medical technology company as executive vice president and chief quality officer, effective September 8. The appointment comes as Jeff Silvestri prepares to retire from the organization.
The Franklin Lakes, New Jersey-based company, which maintains a market capitalization of approximately $50 billion, disclosed the executive transition through a press release issued August 17. BD's stock closed at $183.40 ahead of the announcement.
Quality Leadership at a Critical Juncture
The chief quality officer role carries particular significance for medical technology manufacturers, where regulatory compliance and product quality standards directly impact patient safety and commercial operations. Sorsher will oversee quality operations across BD's global portfolio of medical devices, laboratory equipment, and diagnostic products.
While BD did not disclose details about Silvestri's tenure or Sorsher's previous experience in the announcement summary, the transition represents a planned succession in a key operational leadership position.
Recent Corporate Activity
The leadership announcement comes amid routine corporate activity for the medical technology firm. According to MarginX data, BD is scheduled to present at the 11th Annual Philadelphia C-Level Technology Leadership Summit on August 18, one day after the quality officer announcement.
The company has also declared a $1.05 cash dividend payable September 9, maintaining its regular distribution to shareholders.
MarginX data shows recent insider transactions involving Thomas E. Polen Jr., who exercised options for 43,278 shares while selling 4,152 shares and disposing of 39,126 shares in separate filings.
Market Context
BD operates in the medical technology sector, competing in markets including medication management, diabetes care, infection prevention, and diagnostic systems. The company's quality organization plays a central role in maintaining regulatory approvals and manufacturing standards across its international operations.
The Federal Reserve's next policy decision, scheduled for September 16 according to MarginX data, will provide broader economic context for capital-intensive healthcare manufacturers like BD.
This article was generated by MarginX from public news on 2026-08-17. It is not investment advice.